Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
The last topic covered by Dr. Neal was on exciting work on molecular targets for squamous NSCLC. Long the poor stepchild to adenocarcinoma and other non-squamous subtypes, where new targets have been identified and several exciting targets tested and some now available, squamous NSCLC has largely been defined over the past few years by all of the things not appropriate for it: Avastin (bevacizumab) due to excessive bleeding risk, Alimta (pemetrexed) due to lack of activity, molecular testing for an EGFR mutation or ALK rearrangement due to a low probability of a positive result. But new work from a couple of different groups, as summarized by Dr. Neal, suggests that there are indeed potentially treatable molecular targets in squamous NSCLC, and this could lead to many new trials and therapeutic options for this subset of patients in the coming years.
Here are the video and audio versions of the podcast, along with the transcript and figures for this short program.
Dr. Neal ASCO 2012 LC Highlights Molec Targets Squamous NSCLC Audio Transcript
Dr. Neal ASCO 2012 LC Highlights 2012 Molec Targets Squamous NSCLC Transcript
Dr. Neal ASCO 2012 LC Highlights Molec Targets Squamous NSCLC Figs
We'll end with the question and answer session from that live program, coming up soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…